OBJECTIVES: Severe Aortic stenosis (AS) refers to pathological, clinical and pathophysiological changes associated with decreased aortic valve area, as a consequence of calcification. Transcatheter Aortic Valve Implantation (TAVI) –is targeted at individuals deemed unsuitable candidates for Surgical Aortic Valve Replacement (SAVR) as an alternative to Medical Management (MM). Recently published studies have demonstrated TAVI to be a good use of health care resources in other countries. Our primary objective was to estimate the cost-effectiveness of TAVI for AS compared with MM in Colombia. METHODS: We used an Excel-based probabilistic decision analytic model to evaluate the cost-effectiveness of TAVI for AS compared to MM. A 3 year update of the landmark PARTNER B randomized study was used to inform treatment specific mortality. Rates for adverse events and pacemaker use were taken from a large multinational registry. Model inputs included costs and resource use for inpatient and outpatient treatment in Colombia, and were taken from the published literature and local sources. Utilities and quality of life were estimated from the PARTNER B study. Additional parameters on local epidemiology were obtained from international peer-reviewed literature and private and public official databases. Cost-effectiveness was assessed from a third-payer perspective and over a 20-year time horizon. RESULTS: Our discounted results show that over a patients lifetime, individuals on TAVI obtained 2.55 QALYs and those on MM, 0.83 QALYs. The associated lifetime costs for both interventions were COP$92 million and COP$8 million for TAVI and MM respectively. The incremental cost-effectiveness ratio was therefore $49 million per QALY gained. Although TAVI costs were much higher than MM, TAVI improved the probability of survival by 12%, resulting in an expected survival gain of 1.25 years. CONCLUSIONS: This analysis suggests that TAVI is a cost-effective alternative for the treatment of AS in patients unsuitable for SAVR in Colombia.